Immunocore Holdings plc
IMCR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001671927
No open-market purchases or sales by Immunocore Holdings plc insiders were filed in the last 90 days; 135 institutions reported holding it in 13F filings for Q2 2026, worth $1.66B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −5 vs. previous quarter
- 135
- 13F valueReported value at the end of Q2 2026
- $1.66B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding IMCR, Q2 2026
No superinvestor reported holding IMCR at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Immunocore Holdings plc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 19, 2026 (view filing) | Feb 18 | 1 day | St Leger Tina AmberCHIEF HR OFFICER | SSale | −1.00K | $32.35 | −$32.4K | −47.2%1.12K after | |
| Feb 19, 2026 (view filing) | Feb 18 | 1 day | Berman David MHEAD OF R&D | SSale | −5.96K | $32.35 | −$193.0K | −50.4%5.86K after | |
| Feb 19, 2026 (view filing) | Feb 18 | 1 day | Goll JohnSVP, FINANCE & CAO | SSale | −698 | $32.35 | −$22.6K | −51.7%653 after | |
| Feb 19, 2026 (view filing) | Feb 18 | 1 day | Jallal BahijaCHIEF EXECUTIVE OFFICER | SSale | −11.5K | $32.35 | −$371.2K | −48.2%12.3K after | |
| Dec 8, 2025 (view filing) | Dec 4-5 | 4 days | Berman David MHEAD OF R&D | SSale | −31.9K | $40.26 | −$1.28M | −100.0%0 after | 2 lots10b5-1 |
| Dec 1, 2025 (view filing) | Nov 26-28 | 5 days | Berman David MHEAD OF R&D | SSale | −74.9K | $40.12 | −$3.01M | −100.0%0 after | 2 lots10b5-1 |
| Nov 26, 2025 (view filing) | Nov 24-25 | 2 days | Berman David MHEAD OF R&D | SSale | −18.1K | $40.03 | −$725.3K | −100.0%0 after | 2 lots10b5-1 |
| Oct 2, 2025 (view filing) | Sep 30 | 2 days | Berman David MHEAD OF R&D | SSale | −61.8K | $35.23 | −$2.18M | −100.0%0 after | 10b5-1 |
| Sep 16, 2025 (view filing) | Sep 12-15 | 4 days | Berman David MHEAD OF R&D | SSale | −22.7K | $35.66 | −$810.7K | −100.0%0 after | 3 lots10b5-1 |
| Sep 12, 2025 (view filing) | Sep 10-11 | 2 days | Berman David MHEAD OF R&D | SSale | −50.4K | $36.20 | −$1.82M | −100.0%0 after | 3 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Immunocore Holdings plc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wellington Management Group LLP | 5,721,945 | $181.7M | 0.03% | +1,015,777+21.6% | Added |
| RTW Investments, LP | 4,869,798 | $154.6M | 1.32% | 00.0% | Unchanged |
| FMR LLC | 4,307,246 | $136.8M | 0.01% | −521,908−10.8% | Reduced |
| Primecap Management Co | 3,638,241 | $115.5M | 0.07% | −55,000−1.5% | Reduced |
| Bellevue Group AG | 2,788,245 | $88.5M | 1.86% | −8,558−0.3% | Reduced |
| Tang Capital Management LLC | 2,649,368 | $84.1M | 3.82% | 00.0% | Unchanged |
| Vestal Point Capital, LP | 1,800,000 | $57.1M | 1.34% | −966,868−34.9% | Reduced |
| Two Sigma Investments, LP | 1,648,983 | $52.4M | 0.04% | +627,718+61.5% | Added |
| Millennium Management LLC | 1,597,037 | $50.7M | 0.03% | +359,634+29.1% | Added |
| Armistice Capital, LLC | 1,428,000 | $45.3M | 1.25% | +240,000+20.2% | Added |